Literature DB >> 19824050

NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets.

Jörg Schemies1, Urszula Uciechowska, Wolfgang Sippl, Manfred Jung.   

Abstract

Histone deacetylases (HDACs) are enzymes that cleave off acetyl groups from acetyl-lysine residues in histones and various nonhistone proteins. Four different classes of HDACs have been identified in humans so far. Although classes I, II, and IV are zinc-dependent amidohydrolases, class III HDACs depend on nicotinamide adenine dinucleotide (NAD(+)) for their catalytic activity. According to their homology to Sir2p, a yeast histone deacetylase, the class III is also termed sirtuins. Seven members have been described in humans so far. As sirtuins are involved in many physiological and pathological processes, their activity has been associated with the pathogenesis of cancer, HIV, metabolic, or neurological diseases. Herein, we present an overview over sirtuins including their biology, targets, inhibitors, and activators and their potential as new therapeutic agents.
© 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19824050     DOI: 10.1002/med.20178

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  22 in total

1.  Design and Evaluation of 3-(Benzylthio)benzamide Derivatives as Potent and Selective SIRT2 Inhibitors.

Authors:  Mohammad A Khanfar; Luisa Quinti; Hua Wang; Johnathan Nobles; Aleksey G Kazantsev; Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2015-03-26       Impact factor: 4.345

2.  Development and characterization of 3-(benzylsulfonamido)benzamides as potent and selective SIRT2 inhibitors.

Authors:  Mohammad A Khanfar; Luisa Quinti; Hua Wang; Soo Hyuk Choi; Aleksey G Kazantsev; Richard B Silverman
Journal:  Eur J Med Chem       Date:  2014-02-06       Impact factor: 6.514

Review 3.  Targeting cardiovascular disease with novel SIRT1 pathways.

Authors:  Zhao Zhong Chong; Shaohui Wang; Yan Chen Shang; Kenneth Maiese
Journal:  Future Cardiol       Date:  2012-01

4.  New chemical tools for probing activity and inhibition of the NAD+-dependent lysine deacylase sirtuin 2.

Authors:  Sören Swyter; Matthias Schiedel; Daria Monaldi; Sándor Szunyogh; Attila Lehotzky; Tobias Rumpf; Judit Ovádi; Wolfgang Sippl; Manfred Jung
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

5.  High glucose-induced oxidative stress represses sirtuin deacetylase expression and increases histone acetylation leading to neural tube defects.

Authors:  Jingwen Yu; Yanqing Wu; Peixin Yang
Journal:  J Neurochem       Date:  2016-03-17       Impact factor: 5.372

6.  Investigating the Sensitivity of NAD+-dependent Sirtuin Deacylation Activities to NADH.

Authors:  Andreas S Madsen; Christian Andersen; Mohammad Daoud; Kristin A Anderson; Jonas S Laursen; Saswati Chakladar; Frank K Huynh; Ana R Colaço; Donald S Backos; Peter Fristrup; Matthew D Hirschey; Christian A Olsen
Journal:  J Biol Chem       Date:  2016-02-09       Impact factor: 5.157

7.  Novel thiourea-based sirtuin inhibitory warheads.

Authors:  Wenwen Zang; Yujun Hao; Zhenghe Wang; Weiping Zheng
Journal:  Bioorg Med Chem Lett       Date:  2015-05-30       Impact factor: 2.823

8.  Sirtuin Deacetylation Mechanism and Catalytic Role of the Dynamic Cofactor Binding Loop.

Authors:  Yawei Shi; Yanzi Zhou; Shenglong Wang; Yingkai Zhang
Journal:  J Phys Chem Lett       Date:  2013-02-07       Impact factor: 6.475

9.  Sirt1 in cerebral ischemia.

Authors:  Kevin B Koronowski; Miguel A Perez-Pinzon
Journal:  Brain Circ       Date:  2015-09-30

10.  The Discovery of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine SIRT2 Inhibitors.

Authors:  Paolo Di Fruscia; Ka-Kei Ho; Sasiwan Laohasinnarong; Mattaka Khongkow; Sebastian H B Kroll; Suhail A Islam; Michael J E Sternberg; Karin Schmidtkunz; Manfred Jung; Eric W-F Lam; Matthew J Fuchter
Journal:  Medchemcomm       Date:  2012-03-01       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.